DXCM
DEXCOM INCEvidence as of 2026-09-02Overview · DEXCOM INC
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monito…
Management team
- Mr. Steven R. Pacelli · Executive VP & MD of Dexcom VenturesFind on LinkedIn
- Ms. Sadie M. Stern · Executive VP & Chief Human Resources OfficerFind on LinkedIn
- Mr. Matthew Dolan · Executive Vice President of Strategy, Corporate Development & Dexcom LabsFind on LinkedIn
- Mr. Sean Christensen · Director of Corporate Affairs & Head of Investor RelationsFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−0.1 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.1 of a possible +2; confidence high). Revenue for fiscal Q2 2026 (ended 2026-07-23) was $ 1,308,400,000, up from $ 1,191,900,000 in fiscal Q1 2026 (ended 2026-04-23) and $ 1,157,100,000 in fiscal Q2 2025 (ended 2025-07-23). Gross profit expanded to $ 830,000,000 in fiscal Q2 2026 from $ 750,300,000 in fiscal Q1 2026 and $ 688,800,000 in fiscal Q2 2025, while operating income rose to $ 318,300,000 (about a 24.3% operating margin) in fiscal Q2 2026 from $ 255,300,000 in fiscal Q1 2026 and $ 212,600,000 in fiscal Q2 2025 (about 18.4% then).
Net income and EPS trended higher quarter‑over‑quarter — net income of $ 249,100,000 and diluted EPS of $ 0.64 in fiscal Q2 2026 versus $ 199,500,000 and $ 0.51 in fiscal Q1 2026 and $ 179,800,000 and $ 0.45 in fiscal Q2 2025. Reported common shares outstanding declined to 377,360,765 as of 23 July 2026 from 385,872,977 as of 23 April 2026, cash and cash equivalents were $ 1,105,000,000 as of 30 June 2026 (down slightly from $ 1,118,200,000 as of 31 March 2026), and R&D ran in the $ 145M–$ 153M range, with $ 153,000,000 in fiscal Q2 2026.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue in the quarter ended 30 June 2026 (fiscal Q2 2026) was $1,308,400,000, up from $1,191,900,000 in the quarter ended 31 March 2026 (fiscal Q1 2026) and up from $1,157,100,000 in the quarter ended 30 June 2025 (fiscal Q2 2025).
XBRL companyfacts · 0001093557-26-000143Gross profit was $830,000,000 in fiscal Q2 2026 (ended 30 June 2026), compared with $750,300,000 in fiscal Q1 2026 (ended 31 March 2026) and $688,800,000 in fiscal Q2 2025 (ended 30 June 2025), indicating expanding absolute gross profit over these quarters.
XBRL companyfacts · 0001093557-26-000143Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
The evidence set contains Form 4 insider reporting filings with accession numbers the 4 filed 17 August 2026, the 4 filed 24 August 2026, the 4 filed 25 August 2026, the 4 filed 25 August 2026, the 4 filed 25 August 2026, the 4 filed 25 August 2026, and the 4 filed 28 August 2026.
4 filed 2026-08-17A Form 4 with the 4 filed 28 August 2026 was filed on 2026-08-28 (parse_status: pending).
4 filed 2026-08-28Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum over the past 6 months is +23.3% and ranks in the 82th percentile of the 547-stock research universe on 2026-09-01.
Moneyta signal set · 2026-09-01weakened in debateMomentum over the past 3 months is +22.7% and 12-month momentum (12_1) is +8.1% as of 2026-09-01.
Moneyta signal set · 2026-09-01weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of the recorded timestamps on 2026-09-02 and 2026-09-01, DXCM appears as a holding in multiple ETFs with reported weights including XLV at 0.7%, VO at 0.37%, IWF at 0.1%, SCHX at 0.06%, VOO at 0.06%, SCHB at 0.06%, and IVV at 0.04%.
ETF constituents · market dataThe most-recent reported 13F ownership data (as of the period ended 2025-09-30) shows a single reported institutional holder, Advisors Asset Management, Inc., with a reported value of $794,829 and a quarter-over-quarter value change of -29.0%; the total reported 13F value is $794,829 and holder_count is 1 for that period.
13F holdings · 1 filers · as of 2025-09-30Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple outlets published bullish, retail-oriented headlines on 1 September 2026 highlighting upside potential and recent outperformance versus the S&P 500, citing a six‑month stock gain of about 23.6% and an 11.5% beat versus the S&P over six months.
News · finance.yahoo.com · 2026-09-01A company press announcement on 1 September 2026 says DexCom will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.
News · finance.yahoo.com · 2026-09-01Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Insiders reported aggregate insider sales of "$2.8M" in the 180-day window covered by the parsed filings.
Form 4 · Stern Sadie (EVP Chief People & Culture Off) · $227k sold · 2026-08-27The parsed data show no insider purchases ("bought": "$0") and a net change of "-31021" shares over the same window.
Form 4 · Stern Sadie (EVP Chief People & Culture Off) · $227k sold · 2026-08-27Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model-calculated free cash flow (FCF) growth rate that today's price would justify is 30.13% (implied_growth = 0.3013).
Valuation inputs · SEC XBRL + stored EOD closePrice-to-free-cash-flow (P/FCF, trailing twelve months) is 45.15.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
A favorable read is supported by sequential and year-over-year operating acceleration: revenue (fundamentals-0), gross profit (fundamentals-1), operating income and margin expansion (fundamentals-2), and rising net income and EPS (fundamentals-3) together show improving core profitability; these claims are drawn from the company filing and are strong quarter-level metrics. Share reduction (fundamentals-4) and meaningful trailing free cash flow (valuation-4) combined with a very small long-term debt figure and large cash balance (valuation-5) strengthen the operational cash-generation narrative; these balance-sheet and cash-flow items are well-sourced in the filings and valuation dataset. Market signals — 3–6 month positive momentum and a golden cross (market-0, market-1, market-2) plus positive press on product and international distribution (news-3) — provide corroborating market and story momentum, though technical and media signals are inherently shorter-horizon in strength. While valuation multiples (valuation-1, valuation-2, valuation-3) appear rich on trailing metrics, the model-implied FCF growth required (valuation-0) and strong trailing FCF (valuation-4) indicate the premium is backed by current cash generation; the valuation evidence is moderate in strength and should be weighed against operational improvements.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.32
39 surviving claims rest on 20 distinct sources; the heaviest analyst carries 20% of them, and 95% of what the desk raised survived the debate.
The read is moderately robust: 39 surviving claims drawn from 20 distinct sources provides some breadth, but one analyst accounting for 20% of claims indicates a non-trivial concentration of interpretive weight. The fact that 95% of raised points survived debate suggests internal consistency and low contestation, though many key claims lean on a small set of primary filings (SEC reports and recent Form 4s), so any correction to those documents would materially change the signal set.
Peer context · computed, not argued
12-1 momentum ranks 2nd of 4 in Medical Devices (as of 2026-09-01).
6-month relative strength ranks 1st of 4 in Medical Devices (as of 2026-09-01).
90-day volatility ranks 1st of 4 in Medical Devices (as of 2026-09-01).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
13 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.6 to the score
7 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.6 to the score
3 holdings records· 2 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis−0.3 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
7 filings· 1 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot−1.5 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on DXCM Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.